Vision-restoring chip implanted in first Stargardt patient

Science Corporation has taken an important step in treating Stargardt disease by implanting its innovative vision-restoring chip in its first patient. This breakthrough was presented by Max Hodak, co-founder of Neuralink, at the TechCrunch Disrupt event, where he highlighted that this development is part of a broader effort toward creating brain-computer interfaces (BCI).

Stargardt disease is a form of macular degeneration that affects central vision, significantly impacting the quality of life for those affected. The implantation of this chip represents hope for patients, as it aims to restore visual capability through advanced technology.

## Why it matters This type of innovation not only opens the door to new therapies for visual diseases but could also lay the groundwork for future developments in brain-computer interfaces. The potential to connect the brain with external devices to restore lost functions is a breakthrough that could transform the treatment of various neurological conditions.

## What we know It has been confirmed that Science Corporation has performed the first implantation of its chip in a Stargardt disease patient, marking a milestone in research and development for this condition.

## What remains unclear Specific details about the chip's functionality and initial results regarding visual improvement in the patient have not yet been provided. Furthermore, information about the next steps in the technology's development and its availability for other patients is still pending.